| Effectiveness of exenatide in Asian Indians in a clinical care setting. | |
| | |
MedLine Citation:
|
PMID: 20615102 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: This study reports on the effectiveness of exenatide compared to insulin glargine or NPH insulin in patients with type 2 diabetes mellitus, unable to achieve glycemic control with oral glucose-lowering therapies in a clinical care setting. PATIENTS AND METHODS: Patients with type 2 diabetes mellitus (n = 47) whose glycemia was not controlled adequately with oral hypoglycemic agents at maximum recommended therapeutic doses were initiated on exenatide therapy. Age-, sex-, and body mass index-matched patients receiving insulin glargine (n = 54) or NPH insulin (n = 23) served as controls. Data analysis included glycated hemoglobin, fasting and postprandial plasma glucose, lipid profile, body weight, and the occurrence of hypoglycemia. RESULTS: A statistically significant reduction in glycated hemoglobin value was noted after initiating exenatide (pre-exenatide 9.7 +/- 1.4% vs. post-exenatide 8.7 +/- 1.5%; P < 0.05), which was comparable to values after insulin glargine (9.8 +/- 1.1% vs. 9.0 +/- 1.5%, respectively; P < 0.05) and NPH insulin (9.6 +/- 1.4% vs. 8.9 +/- 1.3%, respectively; P < 0.05). Exenatide therapy was associated with net weight loss (mean, 1.6 kg), but therapy with insulin glargine and NPH insulin was associated with weight gain (1.8 and 2.3 kg, respectively). CONCLUSIONS: In a group of select Asian Indian type 2 diabetes patients with secondary failure to oral hypoglycemic agents seen at a diabetes center, exenatide treatment in combination with oral drug regimens resulted in significant lowering of glycated hemoglobin similar to insulin glargine or NPH insulin but with the additional benefit of weight loss, albeit a small amount. |
| | |
Authors:
|
Chidambarann Sudhakaran; Maryam Fathima; Ranjit Mohan Anjana; Ranjit I Unnikrishnan; Viswanathan Mohan |
Publication Detail:
|
Type: Comparative Study; Journal Article |
Journal Detail:
|
Title: Diabetes technology & therapeutics Volume: 12 ISSN: 1557-8593 ISO Abbreviation: Diabetes Technol. Ther. Publication Date: 2010 Aug |
Date Detail:
|
Created Date: 2010-07-09 Completed Date: 2010-10-08 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100889084 Medline TA: Diabetes Technol Ther Country: United States |
Other Details:
|
Languages: eng Pagination: 613-8 Citation Subset: IM |
Affiliation:
|
Madras Diabetes Research Foundation & Dr. Mohan's Diabetes Specialities Centre, World Health Organization Collaborating Centre for Non-Communicable Diseases, International Diabetes Federation Centre of Education, Gopalapuram, Chennai, India. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Asian Continental Ancestry Group Blood Glucose / drug effects* Body Weight / drug effects Diabetes Mellitus, Type 2 / drug therapy*, metabolism Female Hemoglobin A, Glycosylated / metabolism Humans Hypoglycemia / chemically induced Hypoglycemic Agents / adverse effects, therapeutic use India Insulin / analogs & derivatives, therapeutic use Insulin, NPH / therapeutic use Male Middle Aged Peptides / therapeutic use* Questionnaires Treatment Outcome Venoms / therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Blood Glucose; 0/Hemoglobin A, Glycosylated; 0/Hypoglycemic Agents; 0/Peptides; 0/Venoms; 0/glargine; 11061-68-0/Insulin; 141732-76-5/exenatide; 53027-39-7/Insulin, NPH |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Hand exercise test for the assessment of endothelium-dependent vasodilatation in subjects with type ...
Next Document: The accuracy of home glucose meters in hypoglycemia.